<bill session="118" type="h" number="4005" updated="2024-07-24T15:21:38Z">
  <state datetime="2023-06-12">REFERRED</state>
  <status>
    <introduced datetime="2023-06-12"/>
  </status>
  <introduced datetime="2023-06-12"/>
  <titles>
    <title type="display">Naloxone Affordability Act of 2023</title>
    <title type="short" as="introduced">Naloxone Affordability Act of 2023</title>
    <title type="official" as="introduced">To direct the Comptroller General of the United States to conduct a study on naloxone access.</title>
  </titles>
  <sponsor bioguide_id="K000382"/>
  <cosponsors>
    <cosponsor bioguide_id="B001303" joined="2023-06-12"/>
    <cosponsor bioguide_id="C001119" joined="2023-06-12"/>
  </cosponsors>
  <actions>
    <action datetime="2023-06-12">
      <text>Introduced in House</text>
    </action>
    <action datetime="2023-06-12" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2023-06-16">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="118" type="h" number="3375" relation="unknown"/>
    <bill session="118" type="s" number="1339" relation="unknown"/>
    <bill session="118" type="s" number="1785" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Congressional oversight"/>
    <term name="Drug therapy"/>
    <term name="Drug, alcohol, tobacco use"/>
    <term name="Government studies and investigations"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="Medicaid"/>
    <term name="Medicare"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2023-11-01T15:09:59Z" status="Introduced in House">Naloxone Affordability Act of 2023

This bill requires the Government Accountability Office to study access to and affordability of naloxone (a medication that temporarily reverses opioid overdoses). The study must address matters related to out-of-pocket costs that consumers pay for naloxone and coverage for naloxone as an over-the-counter drug through Medicare, Medicaid, and private health insurance.

Historically, naloxone required a prescription and so was typically covered by health insurance. However, the Food and Drug Administration approved Narcan (a naloxone hydrochloride nasal spray) for use without a prescription on March 29, 2023, and health insurance does not generally cover over-the-counter medications.</summary>
</bill>
